

DAY 3 HIGHLIGHT:

The Grand Finale: Bridging Today's Evidence to Tomorrow's Excellence

By GBCC Scientific Program Committee

Jong Eun Lee (Soonchunhyang Univ. Hospital Cheonan)

Jung Eun Choi (Yeung Nam Univ. Hospital)

Plenary lecture 5

Redefining the Standard: Hypofractionated Locoregional RT for High-Risk Breast Cancer

The landscape of breast cancer radiotherapy is witnessing a pivotal shift. Landmark results from the DBCG Skagen Trial 1 and the French HypoG-01 Trial will be presented by Professor Birgitte Offersen. This collaborative effort provides the much-needed clinical validation for moderately hypofractionated locoregional radiation therapy (RT). While the 40 Gy in 15 fractions regimen has long been the standard for node-negative disease, its application in locoregional RT—required by one in three screened patients—has remained under-evidenced until now. These two large-scale Phase III randomized trials have finally addressed this gap. The trials are expected to demonstrate that the shorter 3-week course is non-inferior to the traditional 5-week regimen regarding lymphedema risk and loco-regional morbidity. Furthermore, the presentation integrates a rigorous validation of the ESTRO consensus for target volume delineation and comprehensive RT quality assurance data.

Plenary lecture 6

Advancing Endocrine Based Therapy to Treat Breast Cancer: The Transition to Genomic Precision

The management of breast cancer is currently undergoing a paradigm shift, moving away from a uniform approach toward a genomically-driven precision model. This evolution is most evident in the field of endocrine-based therapies, where the focus has transitioned from simple estrogen receptor blockade to the strategic overcoming of complex resistance mechanisms. At the heart of this transition is the integration of liquid biopsies and ctDNA analysis. By utilizing real-time genomic monitoring, clinicians can now detect emerging resistance mutations, such as ESR1, far earlier than traditional imaging allows. This proactive detection enables a "switch-of-therapy" strategy, where the endocrine backbone is updated or combined with novel targeted agents before clinical progression occurs. Furthermore, the emergence of next-generation endocrine modulators and selective signaling inhibitors—targeting pathways such as PI3K, AKT, and mTOR—has redefined our therapeutic boundaries. These advancements are not limited to the metastatic setting but are increasingly informing our approach across the entire continuum of care. By precisely targeting the molecular drivers of each tumor, we can significantly extend the efficacy of endocrine-based regimens, thereby delaying the requirement for cytotoxic chemotherapy and preserving the patient's quality of life. Ultimately, this session outlines a future where genomic profiling guides every clinical decision, ensuring that each patient receives the most effective, least toxic, and highly individualized treatment strategy available.

GBCC Consensus Session

Management of Early Breast Cancer in Premenopausal Women: How Different Is It?

The upcoming GBCC Consensus Session, "Management of Early Breast Cancer in Premenopausal Women: How Different Is It?", brings together a distinguished panel of 18 global experts. This inaugural session addresses the unique biological and clinical

challenges inherent in treating younger patients. By synthesizing multidisciplinary perspectives, the panel aims to establish nuanced treatment standards that balance oncological efficacy with long-term quality of life, including fertility preservation and survivorship. This high-level discourse represents a critical step in personalizing care for the premenopausal demographic, ensuring that evolving evidence translates into specialized clinical excellence.

Session for Breast Cancer Survivors

Bridging Clinical Care and Survivorship in Breast Cancer

This comprehensive patient-centered program is designed to empower breast cancer patients and survivors by bridging the gap between clinical expertise and daily life. The sessions progress from foundational knowledge, including genetics (BRCA1/2) and subtypes, to optimized treatment strategies for both early and metastatic stages, featuring the latest in immunotherapy and targeted agents. Beyond clinical care, the program emphasizes holistic recovery, addressing survivorship challenges such as vocational rehabilitation, nutritional management, and weight control. A concluding international forum, featuring global leaders like Fatima Cardoso, highlights the transformative power of patient advocacy and policy-changing support networks across Europe and the US. This curriculum ensures that patients are not merely recipients of care but informed partners in their healing journey, equipped with both medical insights and a supportive global perspective.

Insights of GBCC 2026

At GBCC 2026, four world-renowned experts will headline a specialized wrap-up session, synthesizing the conference's most critical breakthroughs across the breast cancer care continuum.

Surgery

Dr. Peter C. Dubsy highlights tailored surgical interventions that minimize morbidity without compromising oncological safety, focusing on the evolution of de-escalation

strategies.

Early Breast Cancer

Advancements in neoadjuvant therapies and biological profiling are reviewed by Dr. Yeon Hee Park, emphasizing personalized pathways to improve cure rates in early-stage patients.

Advanced Breast Cancer

A deep dive into the shifting treatment paradigm for metastatic disease is provided by Dr. Nadia Harbeck, particularly the integration of novel ADCs and optimized endocrine combinations.

Translational Research

Bridging the gap from bench to bedside, Dr. Pedram Razavi explores the clinical utility of liquid biopsies and genomic profiling in predicting treatment resistance.

This session serves as a high-level executive summary, offering attendees a cohesive roadmap of the innovations that will define clinical practice in the coming year.